Evidence map›Paper›PMID 33851203›Full record

ArticleSchizophrenia bulletin2021

Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses.

Olesya Ajnakina, Tushar Das, John Lally, Marta Di Forti, Carmine M Pariante, Tiago Reis Marques, Valeria Mondelli, Anthony S David, Robin M Murray, Lena Palaniyappan and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Olesya AjnakinaDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID 0000-0003-3987-1236
Tushar DasDepartments of Psychiatry & Medical Biophysics, Robarts Research Institute & Lawson Health Research Institute, University of Western Ontario, London, Ontario, Canada.
John LallyDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Marta Di FortiMRC Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Carmine M ParianteDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
Tiago Reis MarquesDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Valeria MondelliDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.ORCID 0000-0001-8690-6839
Anthony S DavidInstitute of Mental Health, University College London, London, UK.
Robin M MurrayDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Lena PalaniyappanDepartments of Psychiatry & Medical Biophysics, Robarts Research Institute & Lawson Health Research Institute, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0003-1640-7182
Paola DazzanDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
King's College London · GBWestern University · CAInstitute of Mental Health · GBRoyal College of Surgeons in Ireland · IE

Funding

Department of Health PDF-2018-11-ST2-020Medical Research Council MR/M008436/1Medical Research Council MR/S003444/1
6 · The paper itself

Abstract

Treatment resistance (TR) in patients with first-episode psychosis (FEP) is a major cause of disability and functional impairment, yet mechanisms underlying this severe disorder are poorly understood. As one view is that TR has neurodevelopmental roots, we investigated whether its emergence relates to disruptions in synchronized cortical maturation quantified using gyrification-based connectomes. Seventy patients with FEP evaluated at their first presentation to psychiatric services were followed up using clinical records for 4 years; of these, 17 (24.3%) met the definition of TR and 53 (75.7%) remained non-TR at 4 years. Structural MRI images were obtained within 5 weeks from first exposure to antipsychotics. Local gyrification indices were computed for 148 contiguous cortical regions using FreeSurfer; each subject's contribution to group-based structural covariance was quantified using a jack-knife procedure, providing a single deviation matrix for each subject. The latter was used to derive topological properties that were compared between TR and non-TR patients using a Functional Data Analysis approach. Compared to the non-TR patients, TR patients showed a significant reduction in small-worldness (Hedges's g = 2.09, P < .001) and a reduced clustering coefficient (Hedges's g = 1.07, P < .001) with increased length (Hedges's g = -2.17, P < .001), indicating a disruption in the organizing principles of cortical folding. The positive symptom burden was higher in patients with more pronounced small-worldness (r = .41, P = .001) across the entire sample. The trajectory of synchronized cortical development inferred from baseline MRI-based structural covariance highlights the possibility of identifying patients at high-risk of TR prospectively, based on individualized gyrification-based connectomes.

Indexed as

AdolescentAdultAffective Disorders, PsychoticAntipsychotic AgentsCerebral CortexClozapineFemaleFollow-Up StudiesHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNerve NetPsychotic DisordersSchizophreniaYoung AdultAntipsychotic AgentsClozapineclozapinefirst-episode psychosisgyrificationlongitudinalMRIschizophreniatreatment-resistant

Identifiers

PMID33851203
PMCPMC8530394
OpenAlexW3156935282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.